



**NEONATAL MEDICATION PROTOCOLS**

**ZIDOVUDINE**  
 Created by: NCCU  
 Date for review: Oct 2016

NCCU Clinical Guidelines  
 KEMH/PMH  
 Perth, Western Australia

<b>DRUG:</b>	<b>ZIDOVUDINE</b>
<b>PRESENTATION:</b>	Vial: 200mg in 20mL Oral liquid: 50 mg in 5 mL
<b>ACTION &amp; INDICATION:</b>	Antiviral drug for treatment of neonates born to HIV infected women.
<b>DOSE:</b>	<p><b>TERM INFANTS(≥weeks)</b></p> <p>IV: 1.5mg/kg/dose 6 hourly                      ORAL: 4 mg/kg/dose 12 hourly</p> <p><b>PRETERM INFANTS:</b></p> <p><b>&lt;30 weeks</b></p> <p>IV: 1.5 mg/kg/dose 12 hourly                      ORAL: 2 mg/kg/dose 12 hourly</p> <p><b>30-34 weeks</b></p> <p>IV: 1.5mg/kg/dose 12 hourly                      ORAL: 2mg/kg/dose 12 hourly for 2 weeks increasing to 8 hourly for 2 weeks</p> <p><b>Begin treatment within 4 hours of birth and continue for 4 weeks.</b></p>
<b>PREPARATION:</b>	Diluent: Glucose, Saline solutions Intravenous: Take 1mL and dilute to 5mL = 2mg/mL
<b>ADMINISTRATION:</b>	Oral. May be given at any time in regard to feeds. Intravenous : Infuse over 60 minutes
<b>ADVERSE EFFECTS:</b>	Anaemia, neutropenia, leucopenia.
<b>COMMENTS:</b>	Discard vial immediately after use Protect from light.
<b>REFERENCES:</b>	Management of infants born to HIV positive Women Department of Immunology and Infectious Diseases Service PMH July 2012
<b>DATE:</b>	October 2013